Gelesis Holdings Inc., (GLS): Price and Financial Metrics

Gelesis Holdings Inc., (GLS): $0.33

-0.02 (-4.51%)

POWR Rating

Component Grades













Add GLS to Watchlist
Sign Up

Industry: Biotech



in industry

GLS Stock Summary

  • GELESIS HOLDINGS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 4.34% of US listed stocks.
  • The volatility of GELESIS HOLDINGS INC's share price is greater than that of 98.46% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for GLS comes in at -379.94% -- higher than that of just 1.37% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to GELESIS HOLDINGS INC, a group of peers worth examining would be FNGR, AQMS, IMMR, FTCI, and UP.
  • To dig deeper into the stock's financial statements, go to GLS's page on browse-edgar?action=getcompany&CIK=0001805087.

GLS Valuation Summary

  • GLS's price/sales ratio is 0.8; this is 84.31% lower than that of the median Healthcare stock.
  • GLS's EV/EBIT ratio has moved up 8 over the prior 31 months.

Below are key valuation metrics over time for GLS.

Stock Date P/S P/B P/E EV/EBIT
GLS 2023-01-30 0.8 -1.6 -0.5 -1.1
GLS 2023-01-27 1.0 -1.9 -0.6 -1.2
GLS 2023-01-26 1.0 -1.9 -0.6 -1.2
GLS 2023-01-25 1.1 -2.0 -0.6 -1.2
GLS 2023-01-24 1.1 -2.1 -0.7 -1.2
GLS 2023-01-23 1.0 -1.9 -0.6 -1.2

GLS Stock Price Chart Interactive Chart >

Price chart for GLS

GLS Price/Volume Stats

Current price $0.33 52-week high $6.25
Prev. close $0.35 52-week low $0.20
Day low $0.32 Volume 66,390
Day high $0.36 Avg. volume 239,835
50-day MA $0.34 Dividend yield N/A
200-day MA $1.52 Market Cap 24.10M

Gelesis Holdings Inc., (GLS) Company Bio

Gelesis Holdings Inc., a biotherapeutics company, developing a novel category of treatments for weight management and gut related chronic diseases. It develops a mechanobiology technology platform to treat obesity and other chronic diseases related to the GI pathway. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and chronic idiopathic constipation. Gelesis Holdings Inc. was incorporated in 2006 and is based in Boston, Massachusetts.

GLS Latest News Stream

Event/Time News Detail
Loading, please wait...

GLS Latest Social Stream

Loading social stream, please wait...

View Full GLS Social Stream

Latest GLS News From Around the Web

Below are the latest news stories about GELESIS HOLDINGS INC that investors may wish to consider to help them evaluate GLS as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!

William White on InvestorPlace | January 9, 2023

Gelesis to Participate in the 25th Annual ICR Conference

BOSTON, January 05, 2023--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on Monday, January 9, 2023.

Yahoo | January 5, 2023

NYSE to Suspend Trading Immediately in Warrants of Gelesis Holdings, Inc. (GLS WS) and Commence Delisting Proceedings

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of Gelesis Holdings, Inc. (the “Company”), each whole warrant exercisable for one share of common stock — ticker symbol GLS WS — from the NYSE. Trading in the Company’s warrants will be suspended immediately. Trading

Wallstreet:Online | January 4, 2023

Gelesis Holdings Inc. (GLS) is an excellent investment, but the stock is overvalued/undervalued right now

Gelesis Holdings Inc. (NYSE:GLS) marked $0.23 per share on Friday, up from a previous closing price of $0.22. While Gelesis Holdings Inc. has overperformed by 4.39%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GLS fell by -97.65%, with highs and lows ranging from $12.23 to […]

US Post News | December 19, 2022

Why TuanChe Shares Are Trading Lower By 76%? Here Are 48 Stocks Moving In Monday''s Mid-Day Session

Gainers Imago BioSciences, Inc. (NASDAQ: IMGO ) shares jumped 104% to $35.50 after Merck announced it would acquire the company for $36 per share in cash. Nexalin Technology, Inc. (NASDAQ: NXL ) jumped 48% to $2.6650. SeaStar Medical Holding Corporation (NASDAQ: ICU ) shares climbed 47.5% to $5.80. Sotera Health Company (NASDAQ: SHC ) rose 40.4% to $8.45. Barclays, last week, downgraded Sotera Health from Equal-Weight to Underweight and lowered the price target from $7 to $6. NWTN Inc. (NASDAQ: NWTN ) gained 40.3% to $7.13. Kaspien Holdings Inc. (NASDAQ: KSPN ) surged 28.7% to $1.12. Meta Materials Inc. (NASDAQ: MMAT ) shares jumped 25.9% to $2.09 after dropping around 7% on Friday. NeuroOne Medical Technologies Corporation (NASDAQ: NMTC ) gained 25% to $1.0375. NeuroOne, last month, re...

Benzinga | November 21, 2022

Read More 'GLS' Stories Here

GLS Price Returns

1-mo -17.21%
3-mo 17.35%
6-mo -79.75%
1-year -91.75%
3-year N/A
5-year N/A
YTD 13.64%
2022 -97.08%
2021 -1.87%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7163 seconds.